ATE537181T1 - Benzimidazolderivate und deren medizinische verwendungen - Google Patents
Benzimidazolderivate und deren medizinische verwendungenInfo
- Publication number
- ATE537181T1 ATE537181T1 AT04807647T AT04807647T ATE537181T1 AT E537181 T1 ATE537181 T1 AT E537181T1 AT 04807647 T AT04807647 T AT 04807647T AT 04807647 T AT04807647 T AT 04807647T AT E537181 T1 ATE537181 T1 AT E537181T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- halogen atom
- useful
- alkyl group
- substituted alkyl
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102000019055 Nucleoside Transport Proteins Human genes 0.000 abstract 1
- 206010046337 Urate nephropathy Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108091006527 nucleoside transporters Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
- 208000008281 urolithiasis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003432581 | 2003-12-26 | ||
| PCT/JP2004/019290 WO2005063788A1 (ja) | 2003-12-26 | 2004-12-16 | ベンズイミダゾール誘導体及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537181T1 true ATE537181T1 (de) | 2011-12-15 |
Family
ID=34736480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04807647T ATE537181T1 (de) | 2003-12-26 | 2004-12-16 | Benzimidazolderivate und deren medizinische verwendungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7547680B2 (de) |
| EP (1) | EP1698635B1 (de) |
| JP (1) | JP4914611B2 (de) |
| AT (1) | ATE537181T1 (de) |
| CA (1) | CA2550441C (de) |
| ES (1) | ES2377937T3 (de) |
| TW (1) | TW200530224A (de) |
| WO (1) | WO2005063788A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004104022A2 (en) * | 2003-05-16 | 2004-12-02 | The General Hospital Corporation | Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof |
| WO2006012438A2 (en) | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| WO2006115137A1 (ja) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | ２－アミノベンズイミダゾール誘導体及びその医薬用途 |
| AU2006276933A1 (en) * | 2005-07-21 | 2007-02-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of hyperuricemia related health consequences |
| JO3126B1 (ar) * | 2007-11-14 | 2017-09-20 | Janssen Pharmaceutica Nv | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 |
| JP5820269B2 (ja) * | 2008-05-22 | 2015-11-24 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物 |
| CN102216316A (zh) * | 2008-09-05 | 2011-10-12 | 寿制药株式会社 | 取代胺衍生物及以其为有效成分的药物组合物 |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| EP3659601A1 (de) | 2010-03-30 | 2020-06-03 | Ardea Biosciences, Inc. | Behandlung von gicht |
| HUE038265T2 (hu) | 2010-06-15 | 2018-10-29 | Ardea Biosciences Inc | Köszvény és hiperurikémia kezelése |
| CA2813555C (en) * | 2010-10-15 | 2014-11-25 | Ardea Biosciences, Inc. | Methods for treating hyperuricemia and related diseases |
| CN102988326B (zh) * | 2012-12-14 | 2016-01-20 | 贵州信邦制药股份有限公司 | 一种非布索坦片剂及其制备方法和检测方法 |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9413724D0 (en) * | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
| GB9600143D0 (en) | 1996-01-05 | 1996-03-06 | Wellcome Found | Therapeutic compounds |
-
2004
- 2004-12-16 WO PCT/JP2004/019290 patent/WO2005063788A1/ja not_active Ceased
- 2004-12-16 AT AT04807647T patent/ATE537181T1/de active
- 2004-12-16 EP EP04807647A patent/EP1698635B1/de not_active Expired - Lifetime
- 2004-12-16 JP JP2005516622A patent/JP4914611B2/ja not_active Expired - Fee Related
- 2004-12-16 ES ES04807647T patent/ES2377937T3/es not_active Expired - Lifetime
- 2004-12-16 CA CA2550441A patent/CA2550441C/en not_active Expired - Fee Related
- 2004-12-23 TW TW093140242A patent/TW200530224A/zh unknown
-
2006
- 2006-06-23 US US11/473,957 patent/US7547680B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005063788A1 (ja) | 2007-07-19 |
| ES2377937T3 (es) | 2012-04-03 |
| EP1698635A4 (de) | 2009-06-17 |
| JP4914611B2 (ja) | 2012-04-11 |
| US7547680B2 (en) | 2009-06-16 |
| CA2550441A1 (en) | 2005-07-14 |
| EP1698635A1 (de) | 2006-09-06 |
| TW200530224A (en) | 2005-09-16 |
| CA2550441C (en) | 2012-08-28 |
| EP1698635B1 (de) | 2011-12-14 |
| WO2005063788A1 (ja) | 2005-07-14 |
| US20080038242A1 (en) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE537181T1 (de) | Benzimidazolderivate und deren medizinische verwendungen | |
| NO20071042L (no) | 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer | |
| CY1112214T1 (el) | Ενωσεις για χρησεις σχετιζομενες με φλεγμονες και το ανοσοποιητικο | |
| ATE378332T1 (de) | Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon | |
| NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
| ATE540928T1 (de) | Isochinolinverbindungen und ihre medizinische verwendung | |
| DK1719773T3 (da) | Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor | |
| NO20070247L (no) | Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase | |
| EA200500853A1 (ru) | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
| NO20075134L (no) | Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav | |
| NO20073465L (no) | Benzotiazol-derivater | |
| WO2006027628A3 (en) | Naphthalimide derivatives as antiviral agents | |
| JP2010524947A5 (de) | ||
| BR0313407A (pt) | Novo uso de derivados de benzotiazol | |
| WO2005084192A3 (en) | Novel 2’-c-methyl nucleoside derivatives | |
| ATE450498T1 (de) | Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel | |
| EP2100895A4 (de) | Tricyclische verbindung und deren medizinische verwendung | |
| NO20044548L (no) | Fremgangsmate for fremstilling av 6-alkaliden-penemderivater | |
| ATE552252T1 (de) | Isochinolinverbindungen und deren medizinische verwendung | |
| ATE444961T1 (de) | Verbindungen vom hydrazidtyp und deren verwendung in pharmazeutischen zusammensetzungen zur behandlung von herzkreislauferkrankungen | |
| ATE532791T1 (de) | In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung | |
| ATE386735T1 (de) | Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung | |
| DK1493441T3 (da) | Terapeutisk middel for næringskompentenceforstyrrelse i maven | |
| ATE361925T1 (de) | Pyrrolopyridazin-verbindungen |